Skip to main content

Clinical Trials Using Lenalidomide

Review the clinical trials studying lenalidomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-67 of 67

Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for the Treatment of Multiple Myeloma in Ultra-Frail Patients
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
An Attenuated Schedule of the Dara-RVd Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Pre-Transplant Purging and Post-Transplant MRD-Guided Maintenance Therapy with Elranatamab in Patients with High-Risk Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Lenalidomide with Tafasitamab for the Treatment of Relapsed Central Nervous System Diffuse Large B-cell Lymphoma
Status: Active
Location: University of California San Francisco, San Francisco, California
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Valemetostat in Combination with Lenalidomide and Rituximab for the Treatment of Grade 1-3a Relapsed or Refractory Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Venetoclax in Combination with Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Status: Active
Location: See ClinicalTrials.gov
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Status: Active
Location: See ClinicalTrials.gov
Elotuzumab and Lenalidomide after Stem Cell Transplant in Treating Patients with Newly Diagnosed Multiple Myeloma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Isatuximab with or without Lenalidomide in Treating Patients with High Risk Smoldering Plasma Cell Myeloma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Rituximab and Pembrolizumab with or without Lenalidomide in Treating Patients with Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Luspatercept and Lenalidomide for the Treatment of Anemia in Patients with Myelodysplastic Syndromes
Status: Temporarily Closed to Accrual
Location: 5 locations
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: 7 locations
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATLL)
Status: Temporarily Closed to Accrual
Location: 19 locations